Q-FEVER

Q FEVER

CPMP/4048/01, rev. 3

1/7 EMEA 2002
Q-FEVER General points on treatment Q fever is a zoonosis caused by Coxiella burnetii, an obligate intracellular gram-negative bacterium with high infectivity but with relatively low virulence. If used as a biological weapon, it is likely to cause low mortality but high acute morbidity. Transmission from man to man is rare. The incubation period normally varies from 2 to 14 days (1). Up to 50% of infected individuals remain asymptomatic. In acute presentations, symptoms such as headache, malaise, fever, night sweats, cough and pneumonia with pleuritic pain may develop, but the disease is often self-limiting. Alternatively, symptoms may not appear until long after initial infection, so that the patient presents with the chronic forms of the disease. In acute presentations, symptoms such as headache, malaise, fever, night sweats, cough and pneumonia with pleuritic pain may develop, but the disease is often self-limiting. Alternatively, symptoms may not appear until long after natural exposure, so that the patient presents with the chronic forms of infection. Doxycycline is recommended for first line treatment. Both successes and failures with erythromycin in the treatment of Q fever have been reported (2,3). However, recent clinical data have indicated that the times to defervescence that may be achieved with erythromycin, roxithromycin and clarithromycin are similar to that of doxycycline, and that macrolides can be used empirically as second line therapy for acute Q fever (4). Quinolones have been used (2,3,5), and these agents and chloramphenicol may be useful in meningoencephalitis (see chapters on plague and tularemia for dosing recommendations on chloramphenicol). In chronic infection with Coxiella burnetii, which may manifest as endocarditis, the choice of drug and duration of treatment (usually prolonged) has to be considered on an individual basis (2). Combination therapy is normally administered. This guidance covers possible treatment regimens for suspected or confirmed acute clinical cases of Q fever and post exposure preventive therapy. It has been proposed that post-exposure preventive treatment may be effective if begun at days post exposure, (6).
Recommendations are compiled from references 1-6.

2/7 EMEA 2002

Q-FEVER RECOMMENDATIONS In a mass casualty setting parenteral treatment may not be an option and recommendations for oral treatment should be followed. Otherwise oral therapy should be substituted when the patients condition improves. In addition, some products show high bioavailability (e.g. ciprofloxacin and doxycycline) making initial oral treatment an option. Name of active substance Role in treatment and prophylaxis Posology Doxycycline First line treatment in adults and children First line preventive treatment in adults and children 100mg iv twice daily followed by 100 mg orally twice daily Children 100 mg orally twice daily Children Duration of treatment: 1 - 3 weeks Adults Duration of preventive treatment: 1 week (ref 6) Adults Section Treatment of suspected or confirmed clinical cases Post exposure preventive treatment in case of suspected or confirmed exposure to the pathogen
Contra indications Pregnancy and lactation
> 8years and >45 kg: adult dose > 8years and >45 kg: adult dose orally > 8years and <45 kg: 2.2 mg/kg iv > 8years and <45 kg: 2.2 mg/kg orally twice twice daily daily < 8years 2.2. mg/kg iv twice daily < 8years 2.2. mg/kg orally twice daily (maximum 200mg per day) followed (maximum 200mg per day) by the same doses orally Should be considered in view of the prescribing information given in the different Member States. Given the seriousness of the condition the same product as in non-pregnant adults should be considered. It is recommended, when possible, to cease breastfeeding.

3/7 EMEA 2002

Name of active substance Role in treatment and prophylaxis

Section

Treatment of suspected or confirmed clinical cases Duration of treatment: 1- 3 weeks Adults Up to 1g iv 4 times daily followed by 500 mg orally four times daily.
Post exposure preventive treatment in case of suspected or confirmed exposure to the pathogen Duration of preventive treatment: 1 week (ref 6) Adults 500mg orally four times daily

Posology Erythromycin

Second line treatment in adults and children Second line preventive treatment in adults and children

Children

50 mg/kg/day i.v in four divided >35 kg: 500 mg orally, four times daily doses < 35 kg: 50 mg/kg/day orally in two divided doses followed by daily (not to exceed 500 mg four times daily) >35 kg: 500 mg orally, four times daily < 35 kg: 50 mg/kg/day orally in two divided doses daily (not to exceed 500 mg four times daily) Should be considered in view of the prescribing information given in the different Member States. Given the seriousness of the condition the same product as in non-pregnant adults should be considered. It is recommended, when possible, to cease breastfeeding.

4/7 EMEA 2002

Q-FEVER Name of active substance Role in treatment and prophylaxis Posology Clarithromycin Alternative to erythromycin Section Treatment of suspected or confirmed clinical cases Duration of treatment: weeks Post exposure preventive treatment in case of suspected or confirmed exposure to the pathogen Duration of preventive treatment: 1 week (ref 6)
Contra indications Pregnancy and lactation Name of active substance Role in treatment and prophylaxis Posology Roxithromycin Alternative to erythromycin Contra indications Pregnancy and lactation
Adults Adults 500 mg i.v twice daily followed by 500 mg orally twice daily 500 mg orally twice daily Children Children The iv formulation is not recommended in children 7.5 mg/kg twice daily orally; max 250 mg twice 7.5 mg/kg twice daily orally; max daily. Over 40 kg, give adult dose. 250 mg twice daily. Over 40 kg give adult dose. Should be considered in view of the prescribing information given in the different Member States. Given the seriousness of the condition the same product as in non-pregnant adults should be considered. It is recommended, when possible, to cease breastfeeding. Treatment of suspected or confirmed clinical cases Duration of treatment: weeks Adults Post exposure preventive treatment in case of suspected or confirmed exposure to the pathogen Duration of preventive treatment: 1 week Adults
150 mg orally twice daily 150 mg orally twice daily Children Children 8 mg/kg/day orally in two divided 8 mg/kg/day orally in two divided doses doses Should be considered in view of the prescribing information given in the different Member States. Given the seriousness of the condition the same product as in non-pregnant adults should be considered. It is recommended, when possible, to cease breastfeeding.

5/7 EMEA 2002

Name of active substance. Role in therapy and prophylaxis Ciprofloxacin First line treatment in case of meningoencephalitis.

Section Posology

Treatment of suspected or confirmed clinical cases Duration of treatment: 2 -3 weeks Adults 400 mg iv twice daily followed by 500 mg orally twice daily
Post exposure prophylaxis in case of suspected or confirmed exposure to the pathogen NA
Contra indications Pregnancy and lactation Posology Contra indications Pregnancy and lactation Posology Contra indications Pregnancy and lactation
Ofloxacin Alternative to ciprofloxacin
Levofloxacin Alternative to ciprofloxacin
Children Children mg/kg iv twice daily followed by 10-15 mg/kg orally twice daily NA Should be considered in view of the prescribing information given in the different Member States. Given the seriousness of the condition the same product as in non-pregnant adults should be considered. It is recommended, when possible, to cease breastfeeding. NA Adults 400 mg iv twice daily followed by 400 mg orally twice daily Should be considered in view of the prescribing information given in the different Member States. Given the seriousness of the condition the same product as in non-pregnant adults should be considered. It is recommended, when possible, to cease breastfeeding. NA Adults 500mg iv once daily, followed by 500mg orally once daily Should be considered in view of the prescribing information given in the different Member States. Given the seriousness of the condition the same product as in non-pregnant adults should be considered. It is recommended, when possible, to cease breastfeeding.

6/7 EMEA 2002

References 1. Report of WHO group of consultants. Health aspects of Chemical and Biological weapons. Geneva 1970, WHO. 2. Maurin, M., Raoult, D. Q fever. Clin Microbiol Rev. p 518-53. Oct. 1999 3. Caron et. al: Acute Q fever pneumonia. Chest 1998,114:808-813. 4. Gikas etal: Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents Chemother; 45 (12):3644-6, Dec 2001
5. Drancourt M, et al. Eur J Q fever meningoencephalitis in five patients. Eur J Epidemiol 1991 Mar;7(2):134-8
6. United States Army Medical Research Institute of Infectious Disease. http://www.usamriid.army. January 26, 2002

CCTV Camera - IR Type

CSP-3644 Series

Weatherproof IR Camera (40M)

Key Features

- 1/3" SONY Super CCD SensorCCD Sensor Color HAD Color - 520 TVL Resolution Color CCD Camera - Built in 6.0 mm board Lens, 0.00 LUX (IR On) - Approx 40 meters range for night vision - Weather resistant housing for outdoor application

Specification

MODEL Sensor Chip Brand Pixels H.Resolution Infrared Ray LED Illumination CSP-3644-6 1/3 Sony Super HAD CCD 768(H)x582(V) 520TV Lines 54 0Lux(IR ON) More than 48dB 1.0Vp-P/75 AUTO AUTO EE 1/50 (1/60) ~ 1/100000 sec 0.45 Internal Sync. 40Meters 6mm 142(D)x83(W)x84(H)mm DC 12V - 10C ~ +50C
Color IP 66 Level TV Lines IR 40M
S/N Ratio Video Output Auto Gain Control Auto White Balance Exposure Mode

142 mm

Dimension
Electronic Shutter Gamma Correction Synchronizing
Infrared Ray Distance Lens Mount Dimension

Front View

Side View

Operating Temperature

www.kguardsecurity.com

CCTV Camera

Website: http://www.systems-integrators.com.sg Enquiries: sales@systems-integrators.com.sg Tel: +65.68832378 Mobile: +65.97113048 Authorised agent and distributor